ME02915B - Biorazgradivi sastavi za isporuku ljekova - Google Patents
Biorazgradivi sastavi za isporuku ljekovaInfo
- Publication number
- ME02915B ME02915B MEP-2017-260A MEP26017A ME02915B ME 02915 B ME02915 B ME 02915B ME P26017 A MEP26017 A ME P26017A ME 02915 B ME02915 B ME 02915B
- Authority
- ME
- Montenegro
- Prior art keywords
- biodegradable
- drug delivery
- composition
- polyethylene glycol
- amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 29
- 238000012377 drug delivery Methods 0.000 claims 12
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 229920000359 diblock copolymer Polymers 0.000 claims 8
- 229920000428 triblock copolymer Polymers 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims 5
- 239000004626 polylactic acid Substances 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 229920002959 polymer blend Polymers 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 claims 1
- YPUWDDMFYRNEFX-UHFFFAOYSA-N 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane Chemical compound COCCOCCOCCOC.COCCOCCOCCOC YPUWDDMFYRNEFX-UHFFFAOYSA-N 0.000 claims 1
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- 229960002903 benzyl benzoate Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- 229940116333 ethyl lactate Drugs 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- -1 glycerol formal Chemical compound 0.000 claims 1
- 229940074076 glycerol formal Drugs 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- YZWRNSARCRTXDS-UHFFFAOYSA-N tripropionin Chemical compound CCC(=O)OCC(OC(=O)CC)COC(=O)CC YZWRNSARCRTXDS-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
- A01N25/10—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Dentistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Biorazgradivi sastav za isporuku leka obuhvata: (a) biorazgradivi triblok kopolimer koji ima formulu: Av-Bw-Ax gde je A polilaktična kiselina i B je polietilen glikol i v, w i x su broj ponovljenih jedinica u rasponu od 4 do 1090 ili 6 do 1090 i v=x ili v≠x; (b) biorazgradivi diblok kopolimer koji ima formulu: Cy-Az gde je A polilaktična kiselina i C je polietilen glikol sa krajnjim ograničenjem i y i z su broj ponovljenih jedinica u rasponu od 3 do 237 ili 7 do 371, gde je odnos biorazgradivog triblok kopolimera (a) i biorazgradivog CA diblok kopolimera (b) 1:3 do 1:8 ili 1:1 do 1:19 ili 3:2 do 1:19 u navedenom biorazgradivom sastavu leka; i (c) barem jedan farmaceutski aktivan princip.
2. Biorazgradivi sastav za isporuku leka prema patentnom zahtevu 1, gde su v i x ester ponovljene jedinice i w su etilen oksid ponovljene jedinice i dalje obuhvata farmaceutski prihvatljiv nosač.
3. Biorazgradivi sastav za isporuku leka prema patentnom zahtevu 1 ili patentnom zahtevu 2, gde je navedeni sastav injektabilna tečnost na sobnoj temperaturi i formira implant kad se injektira u telo ili su u pitanju male čestice ili šipkasti implanti ili prostorne formulacije.
4. Biorazgradivi sastav za isporuku leka prema bilo kom od patentnih zahteva 1 do 3, gde je navedeni polietilen glikol sa krajnjim ograničenjem metoksi-polietilen glikol.
5. Biorazgradivi sastav za isporuku leka prema bilo kom od patentnih zahteva 1 do 4, gde je barem jedan farmaceutski aktivan princip prisutan u količini od 1 % do 20% (w%/w%) ukupnog sastava i polimeri su prisutni u količini od 20% do 50% (w%/w%) ukupnog sastava.
6. Biorazgradivi sastav za isporuku leka prema bilo kom od patentnih zahteva 1 do 5, gde je triblok kopolimer prisutan u količini od 3,0% do 45% (w%/w%) ukupnog sastava i diblok kopolimer je prisutan u količini od 8,0% do 50% (w%/w%) ukupnog sastava.
7. Biorazgradivi sastav za isporuku leka prema bilo kom od patentnih zahteva 1 do 6, gde je molarni odnos ponovljene jedinice polilaktične kiseline i etilen oksida u sastavu između 0,5 do 3,5 ili 0,5 do 22,3 u tribloku i 2 do 6 ili 0,8 do 13 u dibloku.
8. Biorazgradivi sastav za isporuku leka prema patentnom zahtevu 1, gde navedeni biorazgradivi triblok kopolimer ima formulu: PLAv-PEGw-PLAx i navedeni biorazgradivi diblok kopolimer ima formulu: mPEGy-PLAz. i gde je navedeni odnos biorazgradivog triblok kopolimera (a) i biorazgradivog diblok kopolimera (b) 1:6 u navedenom biorazgradivom sastavu leka.
9. Biorazgradivi sastav za isporuku leka prema patentnom zahtevu 1, gde je navedeni biorazgradivi triblok kopolimer prisutan u količini od 3,0% do 45% (w%/w%) ukupnog sastava i v, w i x su u opsegu od 6 do 1090, gde je navedeni biorazgradivi diblok kopolimer prisutan u količini od 8,0% do 50% (w%/w%) ukupnog sastava i navedeni polietilen glikol sa krajnjim ograničenjem je metoksi-polietilen glikol, gde je navedeni odnos biorazgradivog triblok kopolimera (a) i biorazgradivog diblok kopolimera (b) 1:4 u navedenom biorazgradivom sastavu leka, i gde je navedeni barem jedan farmaceutski aktivan princip prisutan u količini od 1 % do 20% (w%/w%) ukupnog sastava.
10. Biorazgradivi sastav za isporuku leka prema bilo kom od patentnih zahteva 8 do 9, gde je veličina lanca polietilen glikola u opsegu od 200 Da do 12 kDa ili 194 Da do 12 kDa i veličina lanca polietilen glikola sa krajnjim ograničenjem je u opsegu od 100 Da do 2 kDa ili 164 do 2 kDA.
11. Postupak pripreme biorazgradivog sastava za isporuku leka prema patentnom zahtevu 1 gde navedeni postupak obuhvata: (i) rastvaranje u organskom rastvaraču (a) biorazgradivog ABA tip blok kopolimera koji ima formulu: Av-Bw-Ax gde je A polilaktična kiselina i B je polietilen glikol i v, w i x su broj ponovljenih jedinica u rasponu od 4 do 1090 ili 6 do 1090; i (b) biorazgradivi diblok kopolimer koji ima formulu: Cy-Az gde je A polilaktična kiselina i C je polietilen glikol sa krajnjim ograničenjem i y i z su broj ponovljenih jedinica u rasponu od 3 do 237 ili 7 do 371 u odnosu od 1:3 do 1:8 ili 1:1 do 1:19 ili 3,2 do 1:19 (a):(b) kako bi formirali polimernu smešu; i (ii) dodavanje barem jednog farmaceutski aktivnog principa navedenoj polimernoj smeši.
12. Postupak prema patentnom zahtevu 11, dalje obuhvata step od (iii) isparavanje navedenog rastvarača.
13. Postupak prema patentnom zahtevu 11 ili patentnom zahtevu 12, gde je organski rastvarač izabran iz grupe koju čine: benzil alkohol, benzil benzoat, dietilen glikol dimetil eter (Diglim), dietilen glikol monoetil eter (DEGMEE), dimetil izosorbid (DMI), dimetil sulfoksid (DMSO), etil acetat, etil benzoat, etil lactat, etilen glikol monoetil eter acetat, glicerol formal, metil etil keton, metil izobutil keton, N-etil-2-pirolidon, N-metil-2-pirolidinone(NMP), pirolidon-2, tetraglikol, triacetin, tributirin, tripropionin, ili trietilen glikol dimetil eter (triglyme) i njihove smeše.
14. Postupak prema bilo kom od patentnih zahteva 11 do 13, gde je organski rastvarač prisutan u količini od 40% do 74% (w%/w%) ukupnog sastava.
15. Primena biorazgradivog sastava za isporuku leka prema bilo kom od patentnih zahteva 1 do 10, za proizvodnju leka za tretman bolesti kod životinja ili biljaka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428007P | 2010-12-29 | 2010-12-29 | |
| PCT/IB2011/003323 WO2012090070A2 (en) | 2010-12-29 | 2011-12-29 | Biodegradable drug delivery compositions |
| EP11822867.5A EP2658525B1 (en) | 2010-12-29 | 2011-12-29 | Biodegradable drug delivery compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02915B true ME02915B (me) | 2018-04-20 |
Family
ID=45809329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-260A ME02915B (me) | 2010-12-29 | 2011-12-29 | Biorazgradivi sastavi za isporuku ljekova |
Country Status (36)
| Country | Link |
|---|---|
| US (9) | US9023897B2 (me) |
| EP (3) | EP3586825B1 (me) |
| JP (2) | JP6134269B2 (me) |
| KR (1) | KR101741055B1 (me) |
| CN (1) | CN103491946B (me) |
| AU (1) | AU2011350898B2 (me) |
| BR (1) | BR112013016662B1 (me) |
| CA (1) | CA2822854C (me) |
| CL (1) | CL2013001942A1 (me) |
| CO (1) | CO6751290A2 (me) |
| CU (1) | CU24203B1 (me) |
| CY (1) | CY1119829T1 (me) |
| DK (1) | DK2658525T3 (me) |
| EA (1) | EA027046B1 (me) |
| ES (3) | ES2939744T3 (me) |
| FI (1) | FI3586825T3 (me) |
| HR (1) | HRP20171810T1 (me) |
| HU (1) | HUE037349T2 (me) |
| IL (1) | IL227235A (me) |
| LT (1) | LT2658525T (me) |
| MA (1) | MA34832B1 (me) |
| ME (1) | ME02915B (me) |
| MX (1) | MX347090B (me) |
| MY (1) | MY165655A (me) |
| NO (1) | NO2658525T3 (me) |
| NZ (1) | NZ612326A (me) |
| PL (3) | PL2658525T3 (me) |
| PT (1) | PT2658525T (me) |
| RS (1) | RS56550B1 (me) |
| SG (2) | SG191414A1 (me) |
| SI (1) | SI2658525T1 (me) |
| SM (1) | SMT201700550T1 (me) |
| TN (1) | TN2013000267A1 (me) |
| UA (1) | UA112069C2 (me) |
| WO (1) | WO2012090070A2 (me) |
| ZA (1) | ZA201304687B (me) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113549C2 (xx) * | 2012-06-27 | 2017-02-10 | Біорозкладений засіб доставки лікарських засобів для гідрофобних композицій | |
| EP2935311B1 (en) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
| EP2896402A1 (en) | 2014-01-20 | 2015-07-22 | Vect-Horus | Activated neurotensin molecules and the uses thereof |
| US10251937B2 (en) | 2014-01-27 | 2019-04-09 | Medincell | Retro-inverso analogs of spadin display increased antidepressant effects |
| FR3027522B1 (fr) | 2014-10-27 | 2016-12-09 | I Ceram | Composition poreuse chargee en principe actif |
| WO2016144182A1 (en) * | 2015-03-12 | 2016-09-15 | Xpand Biotechnology B.V. | Anhydrous biocompatible composite materials |
| TWI798161B (zh) | 2015-09-21 | 2023-04-11 | 瑞士商梯瓦製藥國際有限公司 | 持續釋放的奧氮平調配物 |
| ES2964696T3 (es) * | 2015-11-16 | 2024-04-09 | Medincell S A | Un método para morselizar y/o dirigir principios farmacéuticamente activos al tejido sinovial |
| KR102615354B1 (ko) | 2016-11-16 | 2023-12-21 | 페르시카 파마슈티컬스 리미티드 | 요통을 위한 항생제 제형 |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| US11612563B2 (en) * | 2017-07-17 | 2023-03-28 | Medincell | Pharmaceutical composition |
| KR20200060729A (ko) | 2017-10-04 | 2020-06-01 | 패션 케미칼즈 게엠베하 운트 코. 카게 | 신규한 폴리락트산의 에스테르 및 이의 조성물 |
| GB201900258D0 (en) | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| EP4027973B8 (en) | 2019-09-13 | 2025-12-17 | Medincell S.A. | Drug delivery formulations |
| CN110638963A (zh) * | 2019-11-01 | 2020-01-03 | 慧生医学科技(徐州)有限公司 | 一种可降解缓释药物组合物及制备方法 |
| GB202010340D0 (en) * | 2020-07-06 | 2020-08-19 | Medincell | Pharmaceutical composition |
| WO2022129417A1 (en) | 2020-12-16 | 2022-06-23 | Medincell | Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19) |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
| BR112023018652A2 (pt) | 2021-03-17 | 2023-10-03 | Medincell S A | Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis |
| CA3217538A1 (en) * | 2021-04-30 | 2022-11-03 | Medincell Sa | New formulation |
| EP4366726A1 (en) | 2021-07-06 | 2024-05-15 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| CA3226943A1 (en) | 2021-08-05 | 2023-02-09 | Medincell S.A. | Pharmaceutical composition |
| WO2024052920A1 (en) * | 2022-09-08 | 2024-03-14 | Ramot At Tel-Aviv University Ltd. | Programmable stimuli-responsive polymeric formulations |
| WO2024149778A1 (en) | 2023-01-10 | 2024-07-18 | Medincell Sa | Olanzapine compositions and methods of use |
| WO2025104289A1 (en) | 2023-11-17 | 2025-05-22 | Medincell S.A. | Antineoplastic combinations |
| WO2025224317A1 (en) * | 2024-04-25 | 2025-10-30 | Medincell S.A. | A method for targeting pharmaceutically active principle in total knee replacement |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US5071643A (en) | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| EP0343850B1 (en) * | 1988-05-23 | 1994-07-20 | The Procter & Gamble Company | Absorbent structures from mixed furnishes |
| US5632727A (en) | 1988-10-03 | 1997-05-27 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5221534A (en) * | 1989-04-26 | 1993-06-22 | Pennzoil Products Company | Health and beauty aid compositions |
| US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
| USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| SK282231B6 (sk) * | 1993-11-19 | 2001-12-03 | Janssen Pharmaceutica N. V. | Farmaceutický prostriedok na liečenie psychotických porúch |
| KR0148704B1 (ko) | 1994-01-10 | 1998-08-17 | 김상응 | 생체분해성 약물전달용 고분자 |
| ATE317690T1 (de) | 1994-04-08 | 2006-03-15 | Qlt Usa Inc | Flüssige zusammensetzungen zur arzneistoffabgabe |
| WO1996021427A1 (en) | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| IL118235A0 (en) | 1996-05-13 | 1996-09-12 | Univ Ben Gurion | Composition and method for forming biodegradable implants in situ and uses of these implants |
| US5711958A (en) * | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US6592899B2 (en) * | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| EP1504047B1 (en) * | 2002-05-03 | 2007-12-12 | Janssen Pharmaceutica N.V. | Polymeric microemulsions |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| US7160551B2 (en) | 2002-07-09 | 2007-01-09 | The Board Of Trustees Of The University Of Illinois | Injectable system for controlled drug delivery |
| US20050112170A1 (en) * | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
| US7262253B2 (en) * | 2003-12-02 | 2007-08-28 | Labopharm, Inc. | Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers |
| US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| WO2006127953A2 (en) * | 2005-05-23 | 2006-11-30 | University Of Utah Research Foundation | Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents |
| JP5401095B2 (ja) * | 2005-11-17 | 2014-01-29 | ゾゲニクス インコーポレーティッド | 無針注射による粘性製剤の送達方法 |
| AR064286A1 (es) * | 2006-12-13 | 2009-03-25 | Quiceno Gomez Alexandra Lorena | Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida |
| US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
| AR070033A1 (es) | 2007-11-06 | 2010-03-10 | Panacea Biotec Ltd | Composiciones inyectables, sus procesos y usos |
| JP2010215562A (ja) | 2009-03-17 | 2010-09-30 | Kansai Univ | 膨隆剤組成物および膨隆剤製造方法 |
-
2011
- 2011-12-29 SG SG2013050364A patent/SG191414A1/en unknown
- 2011-12-29 HR HRP20171810TT patent/HRP20171810T1/hr unknown
- 2011-12-29 KR KR1020137020159A patent/KR101741055B1/ko active Active
- 2011-12-29 NZ NZ612326A patent/NZ612326A/en unknown
- 2011-12-29 ME MEP-2017-260A patent/ME02915B/me unknown
- 2011-12-29 LT LTEP11822867.5T patent/LT2658525T/lt unknown
- 2011-12-29 SI SI201131353T patent/SI2658525T1/en unknown
- 2011-12-29 MA MA36118A patent/MA34832B1/fr unknown
- 2011-12-29 PL PL11822867T patent/PL2658525T3/pl unknown
- 2011-12-29 MY MYPI2013002458A patent/MY165655A/en unknown
- 2011-12-29 CN CN201180068770.4A patent/CN103491946B/zh active Active
- 2011-12-29 ES ES19169971T patent/ES2939744T3/es active Active
- 2011-12-29 HU HUE11822867A patent/HUE037349T2/hu unknown
- 2011-12-29 PT PT118228675T patent/PT2658525T/pt unknown
- 2011-12-29 MX MX2013007682A patent/MX347090B/es active IP Right Grant
- 2011-12-29 SM SM20170550T patent/SMT201700550T1/it unknown
- 2011-12-29 EP EP19169971.9A patent/EP3586825B1/en active Active
- 2011-12-29 BR BR112013016662-2A patent/BR112013016662B1/pt active IP Right Grant
- 2011-12-29 US US13/340,265 patent/US9023897B2/en active Active
- 2011-12-29 FI FIEP19169971.9T patent/FI3586825T3/fi active
- 2011-12-29 AU AU2011350898A patent/AU2011350898B2/en active Active
- 2011-12-29 SG SG10201508568VA patent/SG10201508568VA/en unknown
- 2011-12-29 ES ES11822867.5T patent/ES2647614T3/es active Active
- 2011-12-29 EP EP11822867.5A patent/EP2658525B1/en active Active
- 2011-12-29 UA UAA201309349A patent/UA112069C2/uk unknown
- 2011-12-29 PL PL17181676T patent/PL3257498T3/pl unknown
- 2011-12-29 WO PCT/IB2011/003323 patent/WO2012090070A2/en not_active Ceased
- 2011-12-29 EP EP17181676.2A patent/EP3257498B1/en active Active
- 2011-12-29 DK DK11822867.5T patent/DK2658525T3/da active
- 2011-12-29 RS RS20171154A patent/RS56550B1/sr unknown
- 2011-12-29 ES ES17181676T patent/ES2733915T3/es active Active
- 2011-12-29 EA EA201390783A patent/EA027046B1/ru not_active IP Right Cessation
- 2011-12-29 PL PL19169971.9T patent/PL3586825T3/pl unknown
- 2011-12-29 CA CA2822854A patent/CA2822854C/en active Active
- 2011-12-29 JP JP2013546780A patent/JP6134269B2/ja active Active
- 2011-12-29 NO NO11822867A patent/NO2658525T3/no unknown
-
2013
- 2013-06-21 TN TNP2013000267A patent/TN2013000267A1/fr unknown
- 2013-06-24 ZA ZA2013/04687A patent/ZA201304687B/en unknown
- 2013-06-27 CU CUP2013000091A patent/CU24203B1/es active IP Right Grant
- 2013-06-27 IL IL227235A patent/IL227235A/en active IP Right Grant
- 2013-06-28 CL CL2013001942A patent/CL2013001942A1/es unknown
- 2013-06-28 CO CO13154263A patent/CO6751290A2/es unknown
-
2015
- 2015-02-12 US US14/620,663 patent/US20150157727A1/en not_active Abandoned
- 2015-10-14 US US14/883,177 patent/US20160030581A1/en not_active Abandoned
-
2016
- 2016-10-18 JP JP2016203985A patent/JP6302983B2/ja active Active
-
2017
- 2017-11-22 CY CY20171101219T patent/CY1119829T1/el unknown
-
2018
- 2018-08-02 US US16/053,503 patent/US20190099495A1/en not_active Abandoned
- 2018-09-21 US US16/138,501 patent/US20190192665A1/en not_active Abandoned
-
2020
- 2020-08-03 US US16/983,189 patent/US20210154301A1/en not_active Abandoned
- 2020-10-14 US US17/070,493 patent/US20210038724A1/en not_active Abandoned
-
2022
- 2022-01-10 US US17/571,804 patent/US20220202942A1/en not_active Abandoned
- 2022-09-23 US US17/952,044 patent/US20230091533A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02915B (me) | Biorazgradivi sastavi za isporuku ljekova | |
| Huynh et al. | Functionalized injectable hydrogels for controlled insulin delivery | |
| JP2013533230A5 (me) | ||
| Kempe et al. | In situ forming implants—an attractive formulation principle for parenteral depot formulations | |
| JP2006508127A5 (me) | ||
| RU2005117164A (ru) | Композиции пролонгированного действия с контролируемым высвобождением | |
| RU2008137032A (ru) | Распадающиеся пероральные пленки | |
| NZ597621A (en) | Sustained delivery formulations of risperidone compounds | |
| HK1220628A1 (zh) | 包含高粘度液体载体的可注射控制释放组合物 | |
| SI2659881T1 (en) | Formulation of the delayed release medicinal product | |
| HRP20230890T1 (hr) | Metode za pripremu injektabilnih depo sastava | |
| JP2005523267A5 (me) | ||
| ECSP088951A (es) | /composición farmacéutica estable que contiene docetaxel y método para su fabricación | |
| DE60135486D1 (de) | Zusammensetzungen zur verzögerten abgabe von hydrophoben arzneimitteln und verfahren zu ihrer herstellung | |
| HRP20200567T1 (hr) | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon | |
| FI3655038T3 (fi) | Farmaseuttinen koostumus | |
| CA2877083A1 (en) | Biodegradable drug delivery for hydrophobic compositions | |
| HRP20160368T1 (hr) | Sublingvalni i bukalni filmom obložen pripravak | |
| HRP20201991T1 (hr) | Sustav za isporuku tekućeg polimera za produženu administraciju lijekova | |
| HRP20231667T1 (hr) | Farmaceutski pripravak | |
| WO2011161531A4 (en) | Pharmaceutical composition containing goserelin for in-situ implant | |
| Nguyen et al. | Investigation of the properties of chitosan–Pluronic based nanogel drug delivery systems utilizing various Pluronic types | |
| NL2025092B1 (en) | Solid deep eutectic solvent formulation platform | |
| HRP20170152T1 (hr) | Foto-umreženi derivati hijaluronske kiseline te postupak njihove priprave i upotreba | |
| JP6222984B2 (ja) | 温度応答性生分解性高分子組成物及びその製造方法 |